Quent Capital LLC Has $138,000 Stock Holdings in Becton, Dickinson and Company (NYSE:BDX)

Quent Capital LLC decreased its holdings in Becton, Dickinson and Company (NYSE:BDX) by 12.7% in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 589 shares of the medical instruments supplier’s stock after selling 86 shares during the quarter. Quent Capital LLC’s holdings in Becton, Dickinson and Company were worth $138,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. Livelsberger Financial Advisory bought a new stake in shares of Becton, Dickinson and Company in the 4th quarter worth about $27,000. OLD Point Trust & Financial Services N A bought a new stake in shares of Becton, Dickinson and Company in the 4th quarter worth about $29,000. DiNuzzo Private Wealth Inc. bought a new stake in shares of Becton, Dickinson and Company in the 4th quarter worth about $30,000. Scarborough Advisors LLC bought a new stake in shares of Becton, Dickinson and Company in the 4th quarter worth about $32,000. Finally, Accordant Advisory Group Inc bought a new stake in shares of Becton, Dickinson and Company in the 1st quarter worth about $35,000. Institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Trading Down 0.1 %

Becton, Dickinson and Company stock traded down $0.27 during trading hours on Tuesday, reaching $235.51. 1,276,286 shares of the company’s stock traded hands, compared to its average volume of 1,459,890. The company has a debt-to-equity ratio of 0.70, a quick ratio of 0.97 and a current ratio of 1.85. Becton, Dickinson and Company has a fifty-two week low of $218.75 and a fifty-two week high of $284.48. The firm has a market capitalization of $68.06 billion, a price-to-earnings ratio of 52.22, a PEG ratio of 2.06 and a beta of 0.42. The firm’s 50 day moving average is $233.05 and its 200-day moving average is $236.30.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share for the quarter, beating analysts’ consensus estimates of $3.31 by $0.19. The business had revenue of $4.99 billion for the quarter, compared to the consensus estimate of $5.08 billion. Becton, Dickinson and Company had a net margin of 7.13% and a return on equity of 14.49%. Becton, Dickinson and Company’s revenue for the quarter was up 2.3% on a year-over-year basis. During the same period last year, the company posted $2.96 EPS. On average, analysts predict that Becton, Dickinson and Company will post 13.06 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, September 30th. Investors of record on Monday, September 9th will be given a $0.95 dividend. The ex-dividend date of this dividend is Monday, September 9th. This represents a $3.80 dividend on an annualized basis and a dividend yield of 1.61%. Becton, Dickinson and Company’s dividend payout ratio is 83.70%.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the stock. Evercore ISI decreased their price objective on shares of Becton, Dickinson and Company from $290.00 to $285.00 and set an “outperform” rating on the stock in a report on Tuesday, July 2nd. Barclays increased their price objective on shares of Becton, Dickinson and Company from $305.00 to $312.00 and gave the stock an “overweight” rating in a report on Monday, May 6th. StockNews.com lowered shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a report on Wednesday, July 31st. Citigroup decreased their price objective on shares of Becton, Dickinson and Company from $260.00 to $255.00 and set a “neutral” rating on the stock in a report on Wednesday, July 10th. Finally, The Goldman Sachs Group assumed coverage on shares of Becton, Dickinson and Company in a report on Thursday, May 30th. They set a “buy” rating and a $274.00 price objective on the stock. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, Becton, Dickinson and Company presently has an average rating of “Moderate Buy” and an average target price of $279.50.

Insider Activity at Becton, Dickinson and Company

In related news, EVP Roland Goette sold 3,300 shares of the stock in a transaction that occurred on Wednesday, May 15th. The shares were sold at an average price of $236.73, for a total value of $781,209.00. Following the sale, the executive vice president now directly owns 11,308 shares in the company, valued at approximately $2,676,942.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Becton, Dickinson and Company news, SVP Thomas J. Spoerel sold 300 shares of the firm’s stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $239.31, for a total transaction of $71,793.00. Following the sale, the senior vice president now directly owns 1,976 shares in the company, valued at approximately $472,876.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Roland Goette sold 3,300 shares of the firm’s stock in a transaction that occurred on Wednesday, May 15th. The stock was sold at an average price of $236.73, for a total transaction of $781,209.00. Following the sale, the executive vice president now owns 11,308 shares in the company, valued at $2,676,942.84. The disclosure for this sale can be found here. Insiders have sold 6,900 shares of company stock worth $1,634,112 in the last ninety days. Company insiders own 0.31% of the company’s stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.